Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT06992739 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)
EGFR
Myelosuppression

Interventions

DRUG: Trilaciclib and Sacituzumab Tirumotecan

Sponsor

The First Affiliated Hospital of Xiamen University